SAN CARLOS, Calif., April 25, 2018 /PRNewswire/ -- BioCardia®, Inc., (OTC: BCDA), a leader in the development of comprehensivesolutions for cardiovascular regenerative therapies, today announced the issuance of United States Patent No. 9,945,854 relating to methods of measuring therapeutic potency potential and defining dosages for autologous cell therapy.
The patent provides coverage for BioCardia's CardiAMP Cell Therapy System, which is being studied in two FDA-approved pivotal clinical trials for the large unmet needs of heart failure and chronic myocardial ischemia with refractory angina. The heart failure trial is currently enrolling patients at 10 centers in the United States, while the refractory angina trial is expected to begin patient enrollment later this year.
In prior marrow heart failure studies, therapeutic benefit has been correlated to higher effective doses of specific cell types. One of the primary challenges with point-of-care autologous cell therapy is the variability of a patient's own stem cells. The CardiAMP cell potency assay is designed to address this variability by assessing whether the amount of select cell types from a marrow sample meets a proprietary acceptance criterion derived from data from these past trials. The CardiAMP cell potency assay is an important element of the CardiAMP Cell Therapy System development and is believed to be the first assay of its kind proposed as a quality-based inclusion criterion for a non-cultured autologous cell therapy.
BioCardia Chairman Simon Stertzer, M.D., added, "This issued patent describes one important element of our comprehensive approach to advancing cell therapy for the treatment of heart disease. Data tells us that this personalized medicine element, in conjunction with other elements in the CardiAMP Cell Therapy System, should maximize our probability of clinical and commercial success."
About BioCardia BioCardia, Inc., headquartered in San Carlos, California, is developing regenerative biologic therapies to treat cardiovascular disease. CardiAMP and CardiALLO cell therapies are the Company's biotherapeutic product candidates in clinical development. The Company's current products include the Helix™ transendocardial delivery system and the Morph® steerable guide and sheath catheter portfolio. BioCardia also partners with other biotherapeutic companies to provide its Helix systems and clinical support to their programs studying therapies for the treatment of heart failure, chronic myocardial ischemia and acute myocardial infarction.
Forward Looking StatementsThis press release contains forward-looking statements that are subject to many risks and uncertainties. Forward-looking statements include, among other things, the efficacy and safety of our products and therapies, statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations. Such factors include, among others, the inherent uncertainties associated with developing new products or technologies, regulatory approvals, unexpected expenditures, the ability to raise the additional funding needed to continue to pursue BioCardia's business and product development plans and overall market conditions. We may find it difficult to enroll patients in our clinical trials, which could delay or prevent development of our therapeutic candidates. These forward-looking statements are made as of the date of this press release, and BioCardia assumes no obligation to update the forward-looking statements.
We may use terms such as "believes," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should," "approximately" or other words that convey the uncertainty of future events or outcomes to identify these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained herein, we caution you that forward-looking statements are not guarantees of future performance and that our actual results, and the development of the industry in which we operate may differ materially from the forward-looking statements contained in this presentation. As a result of these factors, we cannot assure you that the forward-looking statements in this presentation will prove to be accurate. Additional factors that could materially affect actual results can be found in BioCardia's Form 10-K filed with the Securities and Exchange Commission on March 16, 2018, including under the caption titled "Risk Factors." BioCardia expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law.
Investor Contact:David McClung, Chief Financial OfficerEmail: investors@BioCardia.comPhone: 650-226-0120
Media Contact:David Schull | Alex XenakisEmail: firstname.lastname@example.org | email@example.comPhone: 212-845-4271 | 212-845-4226
View original content:http://www.prnewswire.com/news-releases/biocardia-receives-new-potency-assay-patent-providing-further-protection-to-autologous-cell-therapy-programs-in-heart-failure-and-refractory-angina-300635954.html
SOURCE BioCardia, Inc.
Subscribe to our Free Newsletters!
Pneumonitis usually refers to inflammation of lung tissue due to various non-infective causes such ...
Fremanezumab-vfrm is used as a preventive treatment for a migraine headache in adult patients. It ...
DOOR syndrome is a rare genetic disorder marked by deafness, short or absent fingernails, abnormal ...View All